This is a demo store. No orders will be fulfilled.

Jackson Foundation patent anti-ERG (anti-ERG) - Primary antibody, specific to ERG, Human IgG1

    Application:
  • Animal Model
  • ELISA
  • Flow Cytometry
  • Functional Assay
  • Host species: Human
  • Reactive species: Cynomolgus monkey,Human,Mouse
  • Isotype: Human IgG1
  • Conjugation: Unconjugated
In stock
Item Number
Ab209912
Grouped product items
SKU Size
Availability
Price Qty
Ab209912-100μg
100μg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$109.90
Ab209912-1mg
1mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$509.90
Ab209912-5mg
5mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$1,399.90
Ab209912-10mg
10mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$2,299.90

Purity≥95% (SDS-PAGE&SEC-HPLC); Endotoxin Level<1.0 EU/mg; Human IgG1; CHO; ELISA, Flow Cytometry, Functional assay, Animal Model; Unconjugated

Basic Description

Product Name Jackson Foundation patent anti-ERG (anti-ERG) - Primary antibody, specific to ERG, Human IgG1
Synonyms Avian erythroblastosis virus E-26 (v-ets) oncogene related antibody | D030036I24Rik antibody | Erg 3 antibody | Erg antibody | ERG/EWS fusion gene, included antibody | ERG/FUS fusion gene, included antibody | ERG/TMPSSR2 fusion gene, included antibody | E
Specifications & Purity Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA
Biochemical and Physiological Mechanisms Transcriptional regulator. May participate in transcriptional regulation through the recruitment of SETDB1 histone methyltransferase and subsequent modification of local chromatin structure.
Host species Human
Specificity ERG
Conjugation Unconjugated
Grade Animal Free, Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated
Product Description

Jackson Foundation patent anti-ERG (anti-ERG) is a monoclonal IgG1 antibody (mAb) directed against the proto-oncogene ETS-related gene (ERG). It has the potential to treat prostate cancer, Ewing's sarcoma, acute myeloid leukemia, endothelial cancer, and colon cancer.

Product Properties

Isotype Human IgG1
Light Chain Type kappa
SDS-PAGE 150 kDa
Purification Method Protein A purified
Concentration See COA
Storage Temp Store at -80°C,Avoid repeated freezing and thawing
Shipped In Ice chest + Ice pads
Stability And Storage Store at -80℃ for 24 months. Upon receipt, it is recommended to aliquot. Avoid freeze/thaw cycle.

Associated Targets(Human)

ERG Tbio Transcriptional regulator ERG (0 Activities)
Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)

Mechanisms of Action

Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References

Images

Jackson Foundation patent anti-ERG (anti-ERG) (Ab209912) - ELISA
Immobilized Recombinant Human ERG protein at 2.0 μg/mL can bind Jackson Foundation patent anti-ERG (anti-ERG) (Ab209912) with the EC50 of 22.39 ng/mL.

Jackson Foundation patent anti-ERG (anti-ERG) (Ab209912) - SEC
The purity of Jackson Foundation patent anti-ERG (anti-ERG) (Ab209912) is more than 95% verified by HPLC.

Certificates(CoA,COO,BSE/TSE and Analysis Chart)

C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:

Solution Calculators

Reviews

Customer Reviews

Shall we send you a message when we have discounts available?

Remind me later

Thank you! Please check your email inbox to confirm.

Oops! Notifications are disabled.